This panel discussion, featuring experts from institutions across the world, will focus on the challenges faced by scientists in developing, manufacturing and commercializing gene therapies. It aims to assess current scientific state-of-the-art in methods of gene editing as well as challenges faced in bringing a prospective therapy to market.
What will you learn?
• The current state-of-the-art in gene editing
• Common targets and mechanisms in current gene therapies
• How to overcome common challenges in manufacturing gene therapies
• The future evolution of gene therapy development and manufacturing
Who may this interest?
• Graduate students, researchers and practitioners working in the multidisciplinary field of gene therapy development
• Individuals with an interest in commercial advanced therapy manufacturing
• Regenerative medicine investors
Head of Commercial Development for Viral Vectors
Lonza (TX, USA)
Xin Swanson serves as the Head of Viral Vector Gene Therapy Commercial Development for Lonza Pharma & Biotech (Basel, Switzerland). She has over 20 years of experience in the pharma/biotech industry, developing viral gene therapies and monoclonal antibody therapeutics. Over the course of her career, Xin has held various positions in R&D, process development and commercial development functions. She has been with Lonza for more than 10 years and has played an instrumental role in the growth of cell and gene therapy business. Xin holds a PhD in Biochemistry from Texas A&M University (TX, USA) and an MBA degree.
Professor of Molecular Medicine, President of the BSGCT, Director (non-exec), Cell and Gene Therapy Catapult,
Imperial College London (London, UK)
Uta is a Professor in Molecular Medicine at Imperial College London, President of the British Society for Gene and Cell Therapy (www.bsgct.org/) from 2017 to 2021, and a non-executive board member of the Cell and Gene Therapy Catapult. Uta has over 20 years experience in developing advanced therapeutic medicines. Her research interests are related to the development of gene and cell therapy-based treatments for cystic fibrosis and other lung diseases. As part of her translational research, Uta has overseen vector and biomarker development, toxicology studies and GMP vector manufacturing. Uta is Co-Investigator on several gene therapy trials, including a recently completed non-viral Phase IIb study.
VP, Business Development & Manufacturing Support
AskBio (NC, USA)
Andy Holt is the Vice President of Business Development and Manufacturing Support at Askbio. He has been working in gene therapy since 2010, focused on the manufacturing and release of viral vectors and cell therapies in a number of commercial and management roles, until recently in contract testing and manufacturing organizations. His work at Askbio focuses on partnership and manufacturing strategies for Askbio’s portfolio of AAV therapeutics. He is based in Raleigh, North Carolina (USA).